*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

翰森製藥
HANSOH PHARMA

# Hansoh Pharmaceutical Group Company Limited
# 翰森製藥集團有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 3692)**

## VOLUNTARY ANNOUNCEMENT
## EQRX'S MARKETING AUTHORIZATION APPLICATION FOR AUMOLERTINIB IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER ACCEPTED BY THE EUROPEAN MEDICINES AGENCY (EMA)

Reference is made to the announcement (the "**Announcement**") of Hansoh Pharmaceutical Group Company Limited (the "**Company**" and together with its subsidiaries, the "**Group**") dated July 23, 2020 in relation to the entry of a strategic collaboration and license agreement (the "**License Agreement**") between the Group and EQRx, INC. ("**EQRx**").

The board of directors (the "**Board**") of the Company is pleased to announce that the European Medicines Agency ("**EMA**") has accepted for review our partner EQRx's marketing authorization application ("**MAA**") for aumolertinib, a novel, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor ("**EGFR-TKI**") being developed and commercialized under the License Agreement, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("**NSCLC**") with sensitizing EGFR mutations and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. This is the second MAA of aumolertinib filed outside of the People's Republic of China. For details of the first MAA filed with the United Kingdom (U.K.)'s Medicines and Healthcare products Regulatory Agency ("**MHRA**"), please refer to the announcement of the Company dated June 15, 2022.

Aumolertinib is one of our key products. As of the date of this announcement, aumolertinib has two indications approved in China and is currently under review by the MHRA for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with sensitizing EGFR mutations and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. The MAA is primarily supported by data from the Phase III study (the "**AENEAS Study**") that evaluated aumolertinib in the first-line treatment of EGFR-mutated locally advanced or metastatic NSCLC. Aumolertinib is also currently being evaluated in several other clinical development programs for lung cancer.

As disclosed in the Announcement, on July 23, 2020, the Group entered into the License Agreement with EQRx, pursuant to which certain subsidiaries of the Group have granted, among others, an exclusive license to permit EQRx to research, develop, manufacture and commercialize aumolertinib and any product containing or comprising of aumolertinib outside of the People's Republic of China. Since the date of the Announcement, EQRx has changed its name to EQRx International, Inc.

**ABOUT AUMOLERTINIB (AUMOLERTINIB MESILATE)**

Aumolertinib, discovered and developed by the Group, marketed as AMEILE® (aumolertinib mesilate) in China, is a novel, third-generation, irreversible EGFR-TKI with favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations. Aumolertinib is approved by the National Medical Products Administration ("**NMPA**") of China for both first-line and second-line treatment of patients with locally advanced or metastatic EGFR-mutated NSCLC.

**ABOUT THE AENEAS STUDY**

The AENEAS Study is a randomized, controlled, double-blind, multicenter phase III trial of aumolertinib versus gefitinib as the first-line treatment for patients with locally advanced or metastatic EGFR-mutated NSCLC. The study met its primary endpoint, demonstrating statistically significant improvement in progression-free survival and a favorable safety profile as compared to gefitinib.

By Order of the Board
**Hansoh Pharmaceutical Group Company Limited**
**Zhong Huijuan**
*Chairlady*

Hong Kong, December 2, 2022

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*